{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:40:12Z","timestamp":1768509612816,"version":"3.49.0"},"posted":{"date-parts":[[2024,2,5]]},"group-title":"Bioengineering","reference-count":43,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,2,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Stem cell therapy holds significant potential for many inflammatory diseases and regenerative medicine applications. However, delivery of therapeutic cells to specific disease sites after systemic administration without indiscriminate trafficking to other non-target tissues is a major limitation of current cell therapies. Here, we describe a novel nanocarrier-directed targeted cell delivery system that enables cell surface coating with dendrimer nanocarriers containing adhesion moieties to serve as a global positioning system \u201cGPS\u201d to guide circulating cells to targeted lesions and mediate the anchoring of cells at the inflammation site. By exploiting cell surface ligands\/receptors selectively and\/or molecular moieties that are highly expressed on activated endothelium in pathologic disease states, nanocarrier-coated cells containing the counterpart binding receptors\/ligands can be enabled to specifically traffic to and dock at vasculature within target lesions. We demonstrate the efficacy of the I-domain fragment of LFA-1 (\n                  <jats:italic>id<\/jats:italic>\n                  LFA-1) complexed to modified nanocarriers to facilitate homing of mesenchymal stem cells (MSCs) to inflamed luminal endothelial cells on which ICAM-1 is highly expressed in a murine model of aortic atherosclerosis. Our method can overcome challenges imposed by the high velocity and dynamic circulatory flow of the aorta to successfully deliver MSCs to atherosclerotic regions and allow for docking of the potentially therapeutic and immunomodulating cells. This targeted cell-delivery platform can be tailored for selective systemic delivery of various types of therapeutic cells to different disease areas.\n                <\/jats:p>","DOI":"10.1101\/2024.02.02.578719","type":"posted-content","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T23:15:12Z","timestamp":1707174912000},"source":"Crossref","is-referenced-by-count":0,"title":["Directing Cell Delivery to Murine Atherosclerotic Aortic Lesions via Targeting Inflamed Circulatory Interface using Nanocarriers"],"prefix":"10.64898","author":[{"given":"Carlos Theodore","family":"Huerta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulexi Y.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elnaz","family":"Zeynaloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emre","family":"Dikici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruna J.","family":"Siahaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sapna K.","family":"Deo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Daunert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2301-0768","authenticated-orcid":false,"given":"Zhao-Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omaida C.","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024020712001094000_2024.02.02.578719v1.1","doi-asserted-by":"crossref","unstructured":"Kean, T. J. , Lin, P. , Caplan, A. I. & Dennis, J. E. MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation. Stem Cells Int 2013, 732742 (2013).","DOI":"10.1155\/2013\/732742"},{"key":"2024020712001094000_2024.02.02.578719v1.2","doi-asserted-by":"publisher","DOI":"10.3727\/096368912X636948"},{"key":"2024020712001094000_2024.02.02.578719v1.3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1524-475X.2010.00616.x","article-title":"Promotion of cutaneous wound healing by local application of mesenchymal stem cells derived from human umbilical cord blood","volume":"18","year":"2010","journal-title":"Wound Repair Regen"},{"key":"2024020712001094000_2024.02.02.578719v1.4","doi-asserted-by":"crossref","unstructured":"Zhou, T. et al. Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol 14, 24 (2021).","DOI":"10.1186\/s13045-021-01037-x"},{"key":"2024020712001094000_2024.02.02.578719v1.5","doi-asserted-by":"crossref","first-page":"e0154053","DOI":"10.1371\/journal.pone.0154053","article-title":"Directing and Potentiating Stem Cell-Mediated Angiogenesis and Tissue Repair by Cell Surface E-Selectin Coating","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"2024020712001094000_2024.02.02.578719v1.6","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1016\/j.ymthe.2018.08.011","article-title":"PDGF Restores the Defective Phenotype of Adipose-Derived Mesenchymal Stromal Cells from Diabetic Patients","volume":"26","year":"2018","journal-title":"Mol Ther"},{"key":"2024020712001094000_2024.02.02.578719v1.7","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2022.0107"},{"key":"2024020712001094000_2024.02.02.578719v1.8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jmbbm.2012.02.018","article-title":"Stiffening of human mesenchymal stem cell spheroid microenvironments induced by incorporation of gelatin microparticles","volume":"11","year":"2012","journal-title":"J Mech Behav Biomed Mater"},{"key":"2024020712001094000_2024.02.02.578719v1.9","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2751"},{"key":"2024020712001094000_2024.02.02.578719v1.10","doi-asserted-by":"crossref","unstructured":"Huerta, C. T. , Voza, F. A. , Ortiz, Y. Y. , Liu, Z.-J. & Velazquez, O. C . Mesenchymal stem cell-based therapy for non-healing wounds due to chronic limb-threatening ischemia: A review of preclinical and clinical studies. Frontiers in Cardiovascular Medicine 10, (2023).","DOI":"10.3389\/fcvm.2023.1113982"},{"key":"2024020712001094000_2024.02.02.578719v1.11","doi-asserted-by":"publisher","DOI":"10.1186\/ar576"},{"key":"2024020712001094000_2024.02.02.578719v1.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2007.00533.x"},{"key":"2024020712001094000_2024.02.02.578719v1.13","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001052"},{"key":"2024020712001094000_2024.02.02.578719v1.14","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-10429-0"},{"key":"2024020712001094000_2024.02.02.578719v1.15","unstructured":"CDC. Heart Disease Facts | cdc.gov. Centers for Disease Control and Prevention https:\/\/www.cdc.gov\/heartdisease\/facts.htm (2022)."},{"key":"2024020712001094000_2024.02.02.578719v1.16","doi-asserted-by":"publisher","DOI":"10.1161\/hc0902.104353"},{"key":"2024020712001094000_2024.02.02.578719v1.17","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2147\/IJN.S355366","article-title":"Targeted Therapy for Inflammatory Diseases with Mesenchymal Stem Cells and Their Derived Exosomes: From Basic to Clinics","volume":"17","year":"2022","journal-title":"Int J Nanomedicine"},{"key":"2024020712001094000_2024.02.02.578719v1.18","doi-asserted-by":"crossref","unstructured":"Planat-Benard, V. , Varin, A. & Casteilla, L . MSCs and Inflammatory Cells Crosstalk in Regenerative Medicine: Concerted Actions for Optimized Resolution Driven by Energy Metabolism. Frontiers in Immunology 12, (2021).","DOI":"10.3389\/fimmu.2021.626755"},{"key":"2024020712001094000_2024.02.02.578719v1.19","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.2001.281.5.C1442"},{"key":"2024020712001094000_2024.02.02.578719v1.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400207"},{"key":"2024020712001094000_2024.02.02.578719v1.21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.10.5231"},{"key":"2024020712001094000_2024.02.02.578719v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)01257-6"},{"key":"2024020712001094000_2024.02.02.578719v1.23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.34.22113"},{"key":"2024020712001094000_2024.02.02.578719v1.24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.7150\/thno\/v01p0277","article-title":"Utilization of I-domain of LFA-1 to Target Drug and Marker Molecules to Leukocytes","volume":"1","year":"2011","journal-title":"Theranostics"},{"key":"2024020712001094000_2024.02.02.578719v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(01)00587-1"},{"key":"2024020712001094000_2024.02.02.578719v1.26","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.18.5.842"},{"key":"2024020712001094000_2024.02.02.578719v1.27","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.20.12.2630"},{"key":"2024020712001094000_2024.02.02.578719v1.28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.1.189"},{"key":"2024020712001094000_2024.02.02.578719v1.29","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.17.8.1517"},{"key":"2024020712001094000_2024.02.02.578719v1.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2007.00566.x"},{"key":"2024020712001094000_2024.02.02.578719v1.31","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.202"},{"key":"2024020712001094000_2024.02.02.578719v1.32","doi-asserted-by":"crossref","unstructured":"Quiroz, H. J. et al. E-Selectin-Overexpressing Mesenchymal Stem Cell Therapy Confers Improved Reperfusion, Repair, and Regeneration in a Murine Critical Limb Ischemia Model. Front Cardiovasc Med 8, 826687 (2021).","DOI":"10.3389\/fcvm.2021.826687"},{"key":"2024020712001094000_2024.02.02.578719v1.33","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.23.1.14-25.2003"},{"key":"2024020712001094000_2024.02.02.578719v1.34","doi-asserted-by":"publisher","DOI":"10.1263\/jbb.99.303"},{"key":"2024020712001094000_2024.02.02.578719v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2009.02.008"},{"key":"2024020712001094000_2024.02.02.578719v1.36","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.3390\/cimb44100320","article-title":"Western Diet-Fed ApoE Knockout Male Mice as an Experimental Model of Non-Alcoholic Steatohepatitis","volume":"44","year":"2022","journal-title":"Curr Issues Mol Biol"},{"key":"2024020712001094000_2024.02.02.578719v1.37","doi-asserted-by":"crossref","unstructured":"Nasiri-Ansari, N. et al. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-\/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. Int J Mol Sci 22, 818 (2021).","DOI":"10.3390\/ijms22020818"},{"key":"2024020712001094000_2024.02.02.578719v1.38","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.3389\/fimmu.2019.02852","article-title":"Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases","volume":"10","year":"2019","journal-title":"Front Immunol"},{"key":"2024020712001094000_2024.02.02.578719v1.39","first-page":"e22316","article-title":"Serpina3c deficiency induced necroptosis promotes non-alcoholic fatty liver disease through \u03b2-catenin\/Foxo1\/TLR4 signaling","volume":"36","year":"2022","journal-title":"FASEB J"},{"key":"2024020712001094000_2024.02.02.578719v1.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2011.03.008"},{"key":"2024020712001094000_2024.02.02.578719v1.41","doi-asserted-by":"publisher","DOI":"10.1080\/14653240802129893"},{"key":"2024020712001094000_2024.02.02.578719v1.42","doi-asserted-by":"crossref","first-page":"e0136026","DOI":"10.1371\/journal.pone.0136026","article-title":"Mesenchymal Stem Cells Stabilize Atherosclerotic Vulnerable Plaque by Anti-Inflammatory Properties","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"2024020712001094000_2024.02.02.578719v1.43","first-page":"1425","article-title":"Human amnion mesenchymal stem cells attenuate atherosclerosis by modulating macrophage function to reduce immune response","volume":"44","year":"2019","journal-title":"Int J Mol Med"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.02.02.578719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:54:00Z","timestamp":1768456440000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.02.02.578719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1101\/2024.02.02.578719","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.3389\/fcvm.2025.1517320","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,2,5]]},"subtype":"preprint"}}